FDA warned DR Vitamin Solutions that its eye drops are unapproved new drugs and misbranded.
What happened
In July 2023, FDA reviewed DR Vitamin Solutions’ website, social media pages, and Amazon storefront and found four eye-drop products offered for sale with claims to treat or prevent cataracts and dry eyes. FDA said the products are unapproved new drugs and are not properly listed with FDA. This was a website review, not an inspection.
What FDA found
The eye-drop products are unapproved new drugs because FDA has no approved application for them and they are not generally recognized as safe and effective for their claimed uses.
FD&C Act §§ 201(p), 505(a), 21 U.S.C. 321(p), 355(a)The products do not meet FDA’s OTC eye-drug monograph because they contain NAC as an active ingredient and are labeled to treat or prevent cataracts, which the monograph does not allow.
FD&C Act § 505G, 21 U.S.C. 355h; OTC Monograph M018The products are misbranded because they are not properly listed with FDA; the Vision Clarity listing has been inactive since January 31, 2020.
FD&C Act §§ 502(o), 510(j)(1), 21 U.S.C. 352(o), 360(j)(1); 21 CFR 207.41Website and social-media claims—such as helping cataracts, dry eyes, and floaters—show the products are intended as drugs.
FD&C Act § 201(g)(1), 21 U.S.C. 321(g)(1)Selling these products in interstate commerce is prohibited because they are unapproved and misbranded drugs.
FD&C Act §§ 301(a), 301(d), 21 U.S.C. 331(a), 331(d)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, with supporting documents. If the company believes it is not in violation, it must explain why and provide supporting information.
Who should pay attention
- retailers and online marketplaces selling eye-care products
- brands marketing NAC eye drops or OTC ophthalmic products
- quality teams at supplement and OTC drug companies
This is a summary. Read the original letter on fda.gov.